ClinicalTrials.gg
CompletedNCT02007278GLOBEUpdated Jul 11, 2017Results posted

Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride

A Phase 4 interventional study of vildagliptin and metformin (combination) and glimepiride in Type 2 Diabetes and Hypoglycemia, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.

Enrollment
92nd of 118
40 · median 162
Started
2014
with 3 others
Phase 4
43 of 119
none open now
Registered
102nd of 119
by date
Lead sponsor
47 of 119
Novartis Pharmaceuticals

Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 92nd largest by enrollment of the 118 interventional ones that give a count, is one of 4 that started in 2014, is one of 43 in phase 4, and was the 102nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About vildagliptin

Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who have not achieved adequate control of their disease prior to treatment with metformin monotherapy in optimal doses.

03

Conditions studied

  • Type 2 Diabetes
  • Hypoglycemia

Keywords

  • diabetes
  • hypoglycemia
  • glycemic variability
  • vildagliptin
  • glimepiride
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • between 8%-10.5% in stable metformin dose (>1500 mg/day), four weeks prior visit 1

Key Exclusion Criteria:

  • Use of other antidiabetic oral therapy during the last 3 months (sulphonylurea, glitazones, GLP-1 analogues, DPP-4 inhibitors), except metformin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    vildagliptin and metformin

    Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks

    Drug: vildagliptin and metformin (combination)

  • Active comparator
    glimepiride and metformin

    Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin

    Drug: glimepiride · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)

    Mean Amplitude of Glycemic Excursions (MAGE) , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement.

    Time frame: Week 12

Secondary outcomes

  1. Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)

    Continuous Overlapping Net Glycemic Action (CONGA) which assesses intra-day glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible. CONGA is calculated in the conventional way with the formula √tқΣt = t1 (Dt -Ď2) / қ - 1, Ď = tқ Σ Dt t = t1 / қ, Dt = Gt-Gt-m (where қ = Observations with an observation n x 60 minutes, G = glucose measure) from the data of continuous monitoring of tissue glucose obtained during the measurement period.

    Time frame: Week 12

  2. Glycemic Variability Measured by Total Standard Deviation (TSD)

    Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept. TSD is calculated conventionally with the formula σ = √Σ (Xi - ῦ) 2 / N (where Xi represents each of the values, ῦ represents the population mean and N is the number of observations) from the data of continuous monitoring of tissue glucose obtained during the measurement.

    Time frame: Week 12

  3. Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12

    Time frame: Screening visit , 12 weeks of treatment

  4. Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline

    Time frame: baseline, 12 weeks of treatment

  5. Number of Patients With Incidence of Hypoglycemia

    Hypoglycemia defined as Glycemia \< 70 mg/dl

    Time frame: 12 weeks

  6. Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment

    MAGE , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. In this endpoint, mean MAGE value is reported for hypo glycemic patients.

    Time frame: 12 weeks

  7. Number of Patients With Any Adverse Events, Serious Adverse Events and Death

    Time frame: 12 weeks

07

Results

Posted Jul 11, 2017

Participant flow

Participant flow — Overall Study
MilestoneVildagliptin and MetforminGlimepiride and Metformin
Started2020
Completed1817
Not completed23
Withdrew: Failure to comply with an eligibility01
Withdrew: Ingestion of drugs not allowed in study01
Withdrew: Incorrect medication administration10
Withdrew: Mis-randomization11

Outcome measures

PrimaryGlycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)

Mean Amplitude of Glycemic Excursions (MAGE) , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement.

Time frame:
Week 12
Reported as:
Mean · mg/dL
Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)
mg/dLVildagliptin and MetforminGlimepiride and Metformin
Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)6.68 ± 1.486.23 ± 1.08
Statistical analysis
  • Vildagliptin and Metformin vs Glimepiride and Metformin · Wilcoxon (Mann-Whitney) · p = 0.4510
SecondaryGlycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)

Continuous Overlapping Net Glycemic Action (CONGA) which assesses intra-day glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible. CONGA is calculated in the conventional way with the formula √tқΣt = t1 (Dt -Ď2) / қ - 1, Ď = tқ Σ Dt t = t1 / қ, Dt = Gt-Gt-m (where қ = Observations with an observation n x 60 minutes, G = glucose measure) from the data of continuous monitoring of tissue glucose obtained during the measurement period.

Time frame:
Week 12
Reported as:
Mean · mg/dL
Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)
mg/dLVildagliptin and MetforminGlimepiride and Metformin
Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)2.92 ± 0.933.01 ± 1.10
SecondaryGlycemic Variability Measured by Total Standard Deviation (TSD)

Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept. TSD is calculated conventionally with the formula σ = √Σ (Xi - ῦ) 2 / N (where Xi represents each of the values, ῦ represents the population mean and N is the number of observations) from the data of continuous monitoring of tissue glucose obtained during the measurement.

Time frame:
Week 12
Reported as:
Mean · mg/dL
Glycemic Variability Measured by Total Standard Deviation (TSD)
mg/dLVildagliptin and MetforminGlimepiride and Metformin
Glycemic Variability Measured by Total Standard Deviation (TSD)1.36 ± 0.401.40 ± 0.42
SecondaryPercentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12
Time frame:
Screening visit , 12 weeks of treatment
Reported as:
Number · percentage of patients
Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12
percentage of patientsVildagliptin and MetforminGlimepiride and Metformin
Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12100.0100.0
SecondaryChange in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline
Time frame:
baseline, 12 weeks of treatment
Reported as:
Mean · Percentage of glycosylated haemoglobin
Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline
Percentage of glycosylated haemoglobinVildagliptin and MetforminGlimepiride and Metformin
Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline1.92 ± 1.12.28 ± 0.79
SecondaryNumber of Patients With Incidence of Hypoglycemia

Hypoglycemia defined as Glycemia \< 70 mg/dl

Time frame:
12 weeks
Reported as:
Number · Patients
Number of Patients With Incidence of Hypoglycemia
PatientsVildagliptin and MetforminGlimepiride and Metformin
Number of Patients With Incidence of Hypoglycemia14
SecondaryMean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment

MAGE , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula Σ λ / χ if λ\> ν (where λ = changes in blood glucose from peak to nadir, χ = number of valid observations, ν = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. In this endpoint, mean MAGE value is reported for hypo glycemic patients.

Time frame:
12 weeks
Reported as:
Mean · mg/dL
Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment
mg/dLVildagliptin and MetforminGlimepiride and Metformin
Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment5.23 ± NA5.53 ± 0.82
SecondaryNumber of Patients With Any Adverse Events, Serious Adverse Events and Death
Time frame:
12 weeks
Reported as:
Number · Patients
Number of Patients With Any Adverse Events, Serious Adverse Events and Death
PatientsVildagliptin and MetforminGlimepiride and Metformin
Any adverse events (serious and non-serious)913
Serious Adverse Events01
Death00

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vildagliptin and Metformin—0/20 (0%)9/20 (45%)
Glimepiride and Metformin—1/20 (5%)13/20 (65%)
Most frequent serious events
Most frequent serious events
EventVildagliptin and MetforminGlimepiride and Metformin
ErysipelasInfections and infestations0/201/20
Most frequent other events
Showing 10 of 49
Most frequent other events
EventVildagliptin and MetforminGlimepiride and Metformin
HypoglycaemiaMetabolism and nutrition disorders1/205/20
Influenza like illnessGeneral disorders3/201/20
TremorNervous system disorders0/203/20
Pain in extremityMusculoskeletal and connective tissue disorders1/202/20
HeadacheNervous system disorders2/201/20
HyperhidrosisSkin and subcutaneous tissue disorders0/202/20
PalpitationsCardiac disorders0/201/20
Ear painEar and labyrinth disorders1/200/20
VertigoEar and labyrinth disorders1/200/20
CataractEye disorders0/201/20

Baseline characteristics

Randomized set

Age, Continuous
Age, Continuous(Years)Vildagliptin and MetforminGlimepiride and MetforminTotal
Mean56.74 ± 10.5855.70 ± 11.5156.25 ± 10.92
Sex: Female, Male
Sex: Female, Male(Participants)Vildagliptin and MetforminGlimepiride and MetforminTotal
Female15823
Male51217
08

Study locations

8 sites
  • Novartis Investigative Site
    Medellín, Antioquia, Colombia
  • Novartis Investigative Site
    Manizales, Caldas 1700, Colombia
  • Novartis Investigative Site
    Bogotá, Cundinamarca, Colombia
  • Novartis Investigative Site
    Chía, Cundinamarca 11001000, Colombia
  • Novartis Investigative Site
    Cali, Valle del Cauca 760001, Colombia
  • Novartis Investigative Site
    Bogotá, 00000, Colombia
  • Novartis Investigative Site
    Cali, Colombia
  • Novartis Investigative Site
    Monteria, Colombia
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2014 to primary completion in Feb 2016, 25 months.

Results were first posted in Jul 2017, 1 year 4 months after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 25 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2013
First posted
Dec 10, 2013
StartActual
Jan 3, 2014
Primary completionActual
Feb 22, 2016
CompletionActual
Feb 22, 2016
Results first posted
Jul 11, 2017
Last update
Jul 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02007278
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Jan 3, 2014
Primary completion
Feb 22, 2016
Completion
Feb 22, 2016
Results posted
Jul 11, 2017
Last update
Jul 11, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vildagliptin · Metformin · Glimepiride

Start the discussion